Delving into the Latest Updates on CD38-specific universal CAR-T(Shenzhen Geno-Immune Medical Institute) with Synapse

Overview

Basic Info

Drug Type

Universal CAR-T

Synonyms-

Target

CD38

Action

modulators

Mechanism

CD38 modulators(Lymphocyte differentiation antigen CD38 modulators), Immunologic cytotoxicity, T lymphocyte replacements

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]

Active Indication

Plasma Cell LeukemiaRefractory acute myeloid leukemiaAcute Lymphoblastic Leukemia+ [2]

Inactive Indication-

Originator Organization

Shenzhen Geno-Immune Medical Institute

Active Organization

Shenzhen Geno-Immune Medical Institute

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T-cell products targeting CLL-1, CD33, CD38 and CD123 in patients with relapsed and refractory AML. The study also aims to learn more about the function of the universal CAR T cells and their persistency in AML patients.

Start Date31 Oct 2023

Sponsor / Collaborator

Shenzhen Geno-Immune Medical Institute

NCT06006741

/ RecruitingPhase 1IIT

Universal CAR-T Cells for the Treatment of Multiple Myeloma

The aim of this study is to assess the feasibility, safety and efficacy of universal CAR T cells targeting multiple myeloma. Another goal of the study is to learn more about the persistence and function of the universal CAR T cells in the body.

Start Date31 Oct 2023

Sponsor / Collaborator

Shenzhen Geno-Immune Medical Institute

NCT03291444

/ RecruitingPhase 1IIT

A Clinical Study of Chimeric Antigen Receptor T Cells Combined With Eps8 Peptide Specific Dendritic Cell for Patients With Relapsed/Refractory Leukemia and Myelodysplastic Syndromes

The main purpose of this study is to verify the safety and potential effectiveness of CART cells combined with peptide specific dendritic cell in relapsed/refractory leukemia.

Start Date05 May 2018

Sponsor / Collaborator

Zhujiang Hospital of Southern Medical University

[+2]

100 Clinical Results associated with CD38-specific universal CAR-T(Shenzhen Geno-Immune Medical Institute)

Login to view more data

100 Translational Medicine associated with CD38-specific universal CAR-T(Shenzhen Geno-Immune Medical Institute)

Login to view more data

100 Patents (Medical) associated with CD38-specific universal CAR-T(Shenzhen Geno-Immune Medical Institute)

Login to view more data

100 Deals associated with CD38-specific universal CAR-T(Shenzhen Geno-Immune Medical Institute)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plasma Cell Leukemia	Phase 1	China	Shenzhen Geno-Immune Medical Institute	31 Oct 2023
Refractory acute myeloid leukemia	Phase 1	China	Shenzhen Geno-Immune Medical Institute	31 Oct 2023
Acute Lymphoblastic Leukemia	Phase 1	China	Shenzhen Geno-Immune Medical Institute	05 May 2018
Anemia, Refractory, With Excess of Blasts	Phase 1	China	Shenzhen Geno-Immune Medical Institute	05 May 2018
Refractory Leukemia	Phase 1	China	Shenzhen Geno-Immune Medical Institute	05 May 2018